Abbott expects to start shipping EleCare infant formula in the coming weeks
Reuters
Published Jul 15, 2022 06:08PM ET
Updated Jul 16, 2022 09:05AM ET
(This July 15 story corrects headline and first paragraph to "in the coming weeks" from "next week")
(Reuters) - Abbott Laboratories (NYSE:ABT) said on Friday it expects to begin releasing EleCare formula in the coming weeks from its recently reopened Sturgis plant, which has been at the center of a baby formula shortage in the United States.
The company had shut down the plant in February and recalled its infant formula, including Similac and EleCare, after reports of bacterial infections in babies who had consumed products made at the facility.
Abbott briefly reopened this plant early last month, but had to shut it down after about two weeks due to thunderstorms and heavy rains.
The company is initially manufacturing EleCare and is working to restart the production of Similac.
EleCare formula is meant for children and babies who cannot tolerate intact protein or may have protein allergies.
Abbott said it is also extending the rebates offered on its products until Sept. 30, in states where the company holds the contract when Similac is unavailable.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.